Carlton Hofferkamp & Jenks Wealth Management LLC Sells 255 Shares of Gilead Sciences, Inc. $GILD

Carlton Hofferkamp & Jenks Wealth Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% in the second quarter, HoldingsChannel reports. The firm owned 5,595 shares of the biopharmaceutical company’s stock after selling 255 shares during the quarter. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Gilead Sciences were worth $642,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. One Wealth Advisors LLC grew its holdings in Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after purchasing an additional 2,364 shares during the period. Ariel Investments LLC boosted its stake in Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 109 shares in the last quarter. Covea Finance lifted its holdings in shares of Gilead Sciences by 69.5% during the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock valued at $5,732,000 after purchasing an additional 21,200 shares in the last quarter. Finally, Swedbank AB boosted its position in shares of Gilead Sciences by 0.8% during the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock valued at $237,393,000 after buying an additional 16,663 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group increased their price target on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a report on Friday, October 17th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Cantor Fitzgerald increased their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a report on Friday, July 25th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the transaction, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,500 shares of company stock worth $8,281,540. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $120.94 on Friday. The business has a fifty day moving average of $115.47 and a 200 day moving average of $111.01. The stock has a market cap of $150.06 billion, a P/E ratio of 24.09, a PEG ratio of 0.83 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.61.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the company posted $2.01 EPS. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.